Towards precision medicine for sepsis patients

Peter Pickkers^{1

2}, Matthijs Kox^{3

4}

Affiliations

¹ Department of Intensive Care Medicine, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Internal mail 710, P.O. Box 9101, Nijmegen, 6500 HB, The Netherlands. peter.pickkers@radboudumc.nl.
² Radboud Center for Infectious Diseases (RCI), Nijmegen, The Netherlands. peter.pickkers@radboudumc.nl.
³ Department of Intensive Care Medicine, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Internal mail 710, P.O. Box 9101, Nijmegen, 6500 HB, The Netherlands.
⁴ Radboud Center for Infectious Diseases (RCI), Nijmegen, The Netherlands.

Editorial

Peter Pickkers et al. Crit Care. 2017.

. 2017 Jan 12;21(1):11.

doi: 10.1186/s13054-016-1583-z.

Peter Pickkers^{1

2}, Matthijs Kox^{3

4}

¹ Department of Intensive Care Medicine, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Internal mail 710, P.O. Box 9101, Nijmegen, 6500 HB, The Netherlands. peter.pickkers@radboudumc.nl.
² Radboud Center for Infectious Diseases (RCI), Nijmegen, The Netherlands. peter.pickkers@radboudumc.nl.
³ Department of Intensive Care Medicine, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Internal mail 710, P.O. Box 9101, Nijmegen, 6500 HB, The Netherlands.
⁴ Radboud Center for Infectious Diseases (RCI), Nijmegen, The Netherlands.

No abstract available

Keywords: Cytokines; HLA-DR; Hyperinflammation; Immune suppression; Markers; PD-1; PD-L1; Personalized; Precision medicine; Sepsis.

References

1. Delano MJ, Ward PA. Sepsis-induced immune dysfunction: can immune therapies reduce mortality? J Clin Invest. 2016;126(1):23–31. doi: 10.1172/JCI82224. - DOI - PMC - PubMed
1. Leentjens J, Kox M, van der Hoeven JG, Netea MG, Pickkers P. Immunotherapy for the adjunctive treatment of sepsis: from immunosuppression to immunostimulation. Time for a paradigm change? Am J Respir Crit Care Med. 2013;187(12):1287–93. doi: 10.1164/rccm.201301-0036CP. - DOI - PubMed
1. Marshall JC. Why have clinical trials in sepsis failed? Trends Mol Med. 2014;20(4):195–203. doi: 10.1016/j.molmed.2014.01.007. - DOI - PubMed
1. Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, Bellomo R, Bernard GR, Chiche JD, Coopersmith CM, et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3) JAMA. 2016;315(8):801–10. doi: 10.1001/jama.2016.0287. - DOI - PMC - PubMed
1. Opal SM, Fisher CJ, Jr, Dhainaut JF, Vincent JL, Brase R, Lowry SF, Sadoff JC, Slotman GJ, Levy H, Balk RA, et al. Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. The Interleukin-1 Receptor Antagonist Sepsis Investigator Group. Crit Care Med. 1997;25(7):1115–24. doi: 10.1097/00003246-199707000-00010. - DOI - PubMed